Clinical Trial Update: Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) [Phase 3]

View source ↗

Summary

Phase 3 study comparing IV/SC risankizumab to IV/SC ustekinumab to evaluate changes in CDAI in adults with moderate-to-severe Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)
• Stelara (ustekinumab)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease (CD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING